Sipuleucel-T: When and for whom to recommend it Journal Article


Author: Slovin, S. F.
Article Title: Sipuleucel-T: When and for whom to recommend it
Abstract: Multiple immunotherapy platforms have been investigated for prostate cancer, but sipuleucel-T still remains the sole approved autologous cellular immune product that can be used in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. While preliminary data for specific checkpoint inhibitors suggest benefit for some patients, leading to durable responses, it has been clear that sipuleucel-T can affect not only the intratumoral milieu but also systemic immune populations. This means that the immune system can respond to sipuleucel-T in such a way that it may also effect an immunomodulatory response to other current and future treatments. It is clear that sipuleucel-T is here to stay; nevertheless, efforts to enhance its efficacy continue. A challenge that continues to be investigated is the question of how and when to use this immune therapy as part of the current continuum of competing approved agents.
Keywords: survival analysis; ipilimumab; radiotherapy; carcinoma; trial; double-blind; multicenter; resistant prostate-cancer; cellular immunotherapy; immune-checkpoint
Journal Title: Oncology (Norwalk)
Volume: 31
Issue: 12
ISSN: 0890-9091
Publisher: C M P Medica LLC * The Oncology Group  
Date Published: 2017-12-15
Start Page: 900
End Page: 912
Language: English
ACCESSION: WOS:000423049600007
PROVIDER: wos
PUBMED: 29297175
Notes: Article -- Source: Wos
Citation Impact
MSK Authors
  1. Susan Slovin
    254 Slovin
Related MSK Work